Drug Profile
Dasolampanel
Alternative Names: NGX-426Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Horizon Pharma
- Developer Raptor Pharmaceutical Corp
- Class Analgesics; Antimigraines
- Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Migraine; Neuropathic pain
Most Recent Events
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 12 Aug 2014 Discontinued - Phase-I for Migraine in USA (PO)
- 12 Aug 2014 Discontinued - Phase-I for Neuropathic pain in USA (PO)